Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: Results from the hypertrophy, insulin, glucose, and electrolytes (HINGE) trial

Circulation

Volumn 123, Issue 2, 2011, Pages 170-177

  Howell, Neil J ^a,c   Ashrafian, Houman ^e   Drury, Nigel E ^a,c   Ranasinghe, Aaron M ^a,c   Contractor, Hussain ^e   Isackson, Henrik ^e   Calvert, Melanie ^d   Williams, Lynne K ^b,c   Freemantle, Nick ^d   Quinn, David W ^a   Green, David ^b   Frenneaux, Michael ^b,c   Bonser, Robert S ^a,c   Mascaro, Jorge G ^a   Graham, Timothy R ^a   Rooney, Stephen J ^a   Wilson, Ian C ^a   Pagano, Domenico ^a,c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b Department of Cardiology ^*  (United Kingdom)

^c Neuropharmacology and Neurobiology Section   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

glucose; heart valves; hypertrophy; insulin

Indexed keywords

ADENOSINE PHOSPHATE; BETA N ACETYLGALACTOSAMINIDASE; GLUCOSE; INOTROPIC AGENT; INSULIN; PLACEBO; POTASSIUM; PROTEIN KINASE B;

ADJUVANT THERAPY; AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; DOUBLE BLIND PROCEDURE; ENZYME PHOSPHORYLATION; FEMALE; FORWARD HEART FAILURE; GLUCOSE INFUSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; INFUSION; INOTROPISM; INSULIN INFUSION; MAJOR CLINICAL STUDY; MALE; POTASSIUM INFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACETYLGLUCOSAMINE; AGED; AMP-ACTIVATED PROTEIN KINASES; AORTIC VALVE; AORTIC VALVE STENOSIS; CARDIAC OUTPUT, LOW; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; HEART VALVE PROSTHESIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; INSULIN; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; POTASSIUM; PROTO-ONCOGENE PROTEINS C-AKT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78751627521     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.945170     Document Type: Article

References (50)

1. Bridgewater B, Keogh BE, Kinsman R, Walton P. Sixth National Adult Cardiac Surgical Database Report. Oxfordshire, UK: Dendrite Clinical Systems; 2008.
2. Attarian DE, Jones RN, Currie WD, Hill RC, Sink JD, Chitwood WR, Wechsler AS. Characteristics of chronic left ventricular hypertrophy induced by subcoronary valvular aortic stenosis, II: response to ischemia. J Thorac Cardiovasc Surg. 1981;81:389-395.
3. Orsinelli DA, Aurigemma GP, Batista S, Kendel S, Gaasch WH. Left ventricular hypertrophy and mortality after aortic valve replacement for aortic stenosis: a high risk subgroup identified by preoperative wall thickness. J Am Coll Cardiol. 1993;5:811-826.
4. Mehta RH, Ruckman D, Das S, Tsai T, Russman P, Karavite D, Monaghan H, Sonnad S, Shea MJ, Eagle KA, Deeb GM. Implications of increased left ventricular mass index on in-hospital outcomes in patients undergoing aortic valve surgery. J Thorac Cardiovasc Surg. 2001;122: 919-928.
5. Tomanek RJ, Palmer PJ, Peiffer GL, Schreiber KL, Eastham CL, Marcus ML. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res. 1986;58: 38-46.
6. Bache RJ, Vrobel TR, Ring WS, Emery RW, Anderson RW. Regional myocardial blood flow during exercise in dogs with chronic left ventricular hypertrophy. Circ Res. 1981;48:76-87.
7. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093-1129.
8. Lydell CP, Chan A, Wambolt RB, Sambanadam N, Parsons H, Bondy GP, Rodrigues B, Popov KM, Harris RA, Brownsley RW, Allard MF. Pyruvate dehydrogenase and the regulation of glucose oxidation in hyper-trophied rat hearts. Cardiovasc Res. 2002;53:841-851.
9. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet. 2004;364:1786-1788.
10. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med. 2007;356:1140-1151.
11. Quinn DW, Pagano D, Bonser, Rooney SJ, Graham TR, Wilson IC, Keogh BE, Townend JN, Lewis ME, Nightingale P. Improved myocardial protection during coronary artery surgery with glucose-insulin-potassium: a randomized controlled trial. J Thorac Cardiovasc Surg. 2006;131: 34-42.
12. Bothe WOM, Beyersdorf F, Doenst T. Glucose-insulin-potassium in cardiac surgery: a meta-analysis. Ann Thorac Surg. 2004;78:1650-1657.
13. Lerch R, Tamm C, Papageogiou I, Benzi RH. Myocardial fatty acid oxidation during ischemia and reperfusion. Mol Cell Biochem. 1992;116: 103-109.
14. Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res. 1988;62:535-542.
15. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-257.
16. Kantor PF, Dyck JR, Lopaschuk GD. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci. 1999;318:3-14.
17. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol. 1974;36:413-459.
18. Iyengar SRK, Charette JP, Iyengar CKS, Wasan S. Myocardial glycogen in prevention of perioperative ischemia injury of the heart. Can J Surg. 1976;19:246-251.
19. Lolley DM, Ray JF, Myers WO, Tewsbury DA. Importance of preop-erative myocardial glycogen levels in human cardiac preservation. J Thorac Cardiovasc Surg. 1978;78:678-687.
20. Das I. Effects of heart work and insulin on glycogen metabolism in the perfused rat heart. Am J Physiol. 1973;224:7-12.
21. Dennis SC, Gevers W, Opie LH. Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol. 1991;23: 1077-1086.
22. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myo-cardial infarction: the time has come for a large prospective trial. Circulation. 1997;96:1152-1156.
23. Jonassen AK, Sack MN, Mjos O, Yellon D. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signalling. Circ Res. 2001;89: 1191-1198.
24. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res. 2008;79:238-248.
25. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12(3-4): 1382-4147.
26. Fulop N, Marchase RB, Chatham JC. Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc Res. 2007;73:288-297.
27. Maganti M, Rao V, Borger MA, Ivanov J, David TE. Predictors of low cardiac output syndrome after isolated aortic valve surgery. Circulation. 2005;112(suppl):I-448-I-452.
28. Devereaux RB, Reichek N. Echocardiographic determination of LV mass in man: anatomic validation of the method. Circulation. 1977;55: 613-619.
29. Devereaux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
30. Cohen G, Feder-Elituv R, Iazetta J, Bunting P, Mallidi H, Bozinovski J, Deemar C, Christakis GT, Cohen EA, Wong BI, McLean RD, Myers M, Morgan CD, Mazer CD, Smith TS, Goldman BS, Naylor CD, Fremes SE. Phase 2 studies of adenosine cardioplegia. Circulation. 1998;98: I225-233.
31. McCulloch CE, Searle SR, ed. Generalized Linear and Mixed Models. New York, NY: John Wiley and Sons Inc; 2001.
32. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-2931.
33. Gradinac S, Coleman GM, Taegtmeyer H, Sweeny MS, Frazier OH. Improved cardiac function with GIK after aorto-coronary bypass grafting. Ann Thorac Surg. 1989;48:284-289.
34. Nesher N, Alghamdi AA, Singh SK, Sever JY, Christakis GT, Goldman BS, Cohen GN, Moussa F, Fremes SE. Troponin after cardiac surgery: a predictor or phenomenon? Ann Thorac Surg. 2008;85:1348-1354.
35. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty J. Preload induces troponin I degradation independently of myocardial ischemia. Circulation. 2001;103:2035-2037.
36. Oates A, Nubani R, Kistler L, Hughey S, Theiss P, Perez-Tamayo RA, Eiferman D, Lonychyna V, Higgins RS. Myocardial protection of insulin and potassium in porcine ischemia-reperfusion model. Surgery. 2009; 146:23-30.
37. Wang Y, Gao E, Tao L, Lau WB, Yuan Y, Goldstein BJ, Lopez BL, Christopher TA, Tian R, Koch W, Ma XL. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation. 2009;119:835-844.
38. Beauloye C, Marsin AS, Bertrand L, Krause U, Hardie DG, Vanoverschelde JL, Hue L. Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett. 2001;505:348-352.
39. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem. 2003;278:39422-39427.
40. Horman SVD, Heath R, Neuman D, Mouton V, Woods A, Schlattner U, Walliman T, Carling D, Hue L, Rider MH. Insulin antagonizes ischemia-induced Thr172 phosphorylation of Ser485/491. J Biol Chem. 2006;281: 5335-5340.
41. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin regulation of 5'-AMP-activated protein kinase and insulin cardiopro-tection after ischemia. Circ Res. 2006;99:61-68.
42. Tian R, Balschi JA. Interaction of insulin and AMPK in the ischemic heart: another chapter in the book of metabolic therapy? Circ Res. 2006; 99:3-5.
43. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura T, Nakamura S, Yoshida M. Impact of acute hyperglycaemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J. 2003;146: 674-678.
44. Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C, Kimura K, Miyazaki S, Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue T, Saito F, Ogawa H. Acute hyperglycaemia is associated with adverse outcomes after acute myocardial infarction in the coronary intervention era. Am Heart J. 2005;150:814-820.
45. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger MA. Hyperglycaemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005;130:1144.e1141-1144.e1148.
46. Su H, Sun X, Zhang HF, Yu QJ, Huang C, Wang XM, Luan RH, Wang HC, Gao F. Acute hyperglycaemia exacerbates myocardial ischemia/ reperfusion injury and blunts cardioprotective effect of GIK. Am J Phsyiol Endocrinol Metab. 2007;293:E629-E635.
47. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen YF, Darley-Usmar V, Oparil S, Chatham JC. Protein O-GlcNAcylation: a new signalling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol. 2009;296:13-28.
48. Fulop N, Zhang Z, Marchase RB, Chatham JC. Glucosamine cardiopro-tection in perfused rat hearts associated with increased O-linked N-acetyl-glucosamine protein modification and altered p38 activity. Am J Physiol Heart Circ Physiol. 2007;292:H2227-H2236.
49. Liu J, Marchase RB, Chatham JC. Glutamine induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell Cardiol. 2007;42:177-185.
50. Liu J, Marchase RB, Chatham JC. Increased O-GlcNAc levels during reperfusion leads to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol. 2007;293:H1391-H1399.